Integra LifeSciences Posts Street Beating Earnings, Backs FY22 Guidance
Integra LifeSciences Holdings Corp (NASDAQ:IART) reported Q1 FY22 sales of $376.6 million, +4.6% Y/Y on a reported basis and 5.6% organic, beating the consensus of $362.04 million. Adjusted EPS stood at $0.74, ahead of The Street estimate of $0.68. Integra Lifesciences in Q1 also announced the launch of its NeuraGen 3D nerve guide matrix,…
Benzinga ·
Benzinga
